Hylle Boulevard 34
Malmö 215 32
Sweden
46 7 08 88 21 72
https://www.cyxone.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 3
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Kjell G. Stenberg Ph.D. | Chief Executive Officer | N/A | N/A | 1952 |
Ms. Malin Lindskog | Chief Financial Officer | N/A | N/A | 1992 |
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, Sweden.
Cyxone AB (publ)s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.